PHARMACEUTICAL company iX Biopharma has appointed a new chief commercial officer (CCO) to develop the Catalist-listed company's global commercial strategies.

Speciality pharmaceutical company iX Biopharma has appointed Eva Tan as its new chief commercial officer.  Tan previously served as iX Biopharma’s director of corporate and commercial strategy since 2019, and commercial director from 2017 to 2019. As director of corporate and commercial strat...

iX Biopharma has obtained approval and registration by the Health Sciences Authority (HSA) for Silcap, a sildenafil drug that is used in the treatment of male erectile dysfunction on Oct 20. The drug, which is iX Biopharma’s second treatment for male erectile dysfunction after Wafesil, has been de...

Phillip Securities has initiated coverage on iX Biopharma with a “buy” recommendation and target price of 45.5 cents. This comes as the brokerage believes the biotech company could finally turn profitable in FY21 as its revenue could be bumped up by as much as 250%. It notes that iX Biopharma ha...

IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to-market and potentially saving on testing costs.

iX Biopharma’s wholly-owned subsidiary iX Syrinx has obtained the good manufacturing practice (GMP) licence issued by the Therapeutic Goods Administration (TGA) of Australia for its testing laboratory in the state of Victoria on September 28. With the new licence, iX Biopharma will now be able to ...

IX Biopharma on Monday said it has obtained a licence in Australia to bring its product testing in-house, improving speed-to market and potentially saving on testing costs.

iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology. The patent will expire on October 11, 2033, and will provide key intellectual property protection for the company's WaferiX delivery technology platform in Israel. The company has also received a patent from t...

CATALIST-LISTED iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology, it said in a bourse filing on Monday.

CATALIST-LISTED iX Biopharma has received a second notice of allowance from the United States Patent and Trademark Office (USPTO) which enhances intellectual property (IP) protection for the former's lead drug Wafermine.